Accessibility Tools

Web Accessibility plugin by DJ-Extensions.com
Skip to main content

Thai Red Cross Plasma Fractionation Centre

The Thai Red Cross Plasma Fractionation Centre received the royal blessing from Her Royal Highness Princess Maha Chakri Sirindhorn, who presided over the groundbreaking ceremony on March 20, 2013. Construction was completed on May 8, 2015. The centre has been named “The Thai Red Cross Plasma Fractionation Centre, in honor of Her Royal Highness Princess Maha Chakri Sirindhorn’s 5th Cycle Birthday Anniversary on April 2, 2015.” The royal permission was granted to display the initials “S.T.” on the building’s sign.

The centre comprises eight buildings and various systems, covering a total area of approximately 9,850 square meters, including:

  • Office building
  • Production building
  • Equipment and engineering systems building
  • Animal testing building
  • Alcohol distillation tower
  • Waste storage building
  • Wastewater treatment building
  • Water reservoir

The Thai Red Cross Plasma Fractionation Centre began the pilot production of three plasma-derived products in 2015-2016: Albumin, Factor VIII, and Intravenous Immunoglobulin (IVIG). These products were developed using advanced technology transferred from Green Cross Corporation (GCC) of South Korea and were ready for sale in 2017. The maximum production capacity will utilize 200,000 liters of plasma per year. In the initial 1-2 years, 81,000 liters of plasma will be used for production, and from 2017 to 2027, production capacity will expand to 100,000-180,000 liters per year, aligning with the volume of plasma collected from both whole blood donors and direct plasma donors (plasmapheresis).

This initiative aims to produce sufficient plasma products to meet domestic demand, replacing imports and delivering significant benefits to the public and the nation. Excess plasma will be utilized for drug production, preventing waste and conserving foreign currency. The project enhances the healthcare of domestic patients by providing access to high-quality plasma products that meet international standards, resulting in improved public health and quality of life.